Epidemiologic Trends,Occurrence of Extended-Spectrum β-Lactamase Production,and Performance of Ertapenem and Comparators in Patients with Intra-Abdominal Infections: Analysis of Global Trend Data from 2002

Abstract

Background:

The Study for Monitoring Antimicrobial Resistance Trends (SMART) is an ongoing surveillance study to monitor worldwide resistance trends among aerobic and facultative anaerobic gram-negative bacilli isolated from intra-abdominal infections (IAIs). Results from SMART in 2002 through 2005 have been reported; this report summarizes aggregated data from SMART 2002–2007 to identify epidemiologic trends over time.

Methods:

A cumulative total of 446 sites were involved, of which 119, 166, 66, 28, and 67 were in Asia/Pacific, Europe, Latin America, Middle East/Africa, and North America, respectively.

Results:

A total of 34,635 isolates were collected from IAIs during 2002–2007, of which 32,113 (92.7%) were from 12 species. The organisms isolated most commonly were Escherichia coli (47.6%), Klebsiella pneumoniae (12.9%), and Pseudomonas aeruginosa (9.5%). The most frequent infection source associated with the 12 most common organisms consistently was peritoneal (46%), followed by intestine (15.8%) and liver (3.2%), with the majority of the organisms originating from inpatients (90.7%), followed by outpatients (4.3%) and undetermined sources (5.0%). Approximately 52% of these isolates were from patients with a hospital stay of ≥48 h, with 45.5% from patients with a hospital stay of <48 h. Overall, ertapenem and imipenem consistently were the most effective antibiotics, whereas resistance to other agents was more common.

Conclusions:

Escherichia coli was the organism isolated most frequently from IAIs, of which the majority were from peritoneal and intestinal sources. Only the carbapenems maintained good activity against the majority of clinical isolates.

Get full access to this article

View all access options for this article.

References

Bochicchio

, Baquero

, Hsueh

et al.

In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002–2004: Results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

Surg Infect, 2006; 7:537–545.

Rossi

, Baquero

, Hsueh

P-R

et al.

In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

J Antimicrob Chemother, 2006; 58:205–210.

Diekema

, Pfaller

, Turnidge

et al. Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY antimicrobial resistance surveillance centers worldwide, 1998. Microb Drug Resist, 2000; 6:213–221.

Paterson

, Rossi

, Baquero

et al.

In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)

J Antimicrob Chemother, 2005; 55:965–973.

Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Thirteenth Information Supplement M100-S18. Clinical Laboratory Standards Institute: Villanova, PA, 2008.

Stone

, O'Hara

, Williams

et al. Comparison of disk diffusion, VITEK 2, and broth microdilution antimicrobial susceptibility test results for unusual species of Enterobacteriaceae. J Clin Microbiol, 2007; 45:340–346.

Lockhart

, Abramson

, Beekmann

et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care units in the United States between 1993 and 2004. J Clin Microbiol, 2007; 45:3352–3359.

Baquero

, Hsueh

P-R

, Paterson

et al.

In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

Surg Infect, 2009; 10:99–104.

Goossens

, Grabein

. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997–2004) Diagn Microbiol Infect Dis, 2005; 53:257–264.

10.

Hirakata

, Matsuda

, Miyazaki

et al.

Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002)

Diagn Microbiol Infect Dis, 2005; 52:323–329.

11.

Sader

, Hsiung

, Fritsche

et al. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis, 2007; 57:341–344.

12.

Chow

, Satishchandran

, Snyder

et al.

In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Surg Infect, 2006; 6:439–447.

13.

Bissett

. ESBL-producing Enterobacteriaceae: Controlling the spread of infection. Br J Nursing, 2007; 16:644–647.

14.

Bush

. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infection, 2008; 14:134–143.

15.

Canton

, Novais

, Valverde

et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect, 2008; 14:21–24.

16.

Nicolas-Chanoine

, Jarlier

. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infection, 2007; 14:111–116.

17.

Pitout

, Laupland

. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis, 2008; 8:159–166.

18.

Bukholm

, Tannaes

, Kjelsberg

, Smith-Erichsen

. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol, 2002; 23:441–446.

19.

Dorsey

, Borneo

, Sun

et al. A heterogeneous outbreak of Enterobacter cloacae and Serratia marcescens infections in a surgical intensive care unit. Infect Control Hosp Epidemiol, 2002; 21:465–469.

20.

Gastmeier

, Groneberg

, Weist

, Ruden

. A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: Identification of transmission and intervention. Am J Infect Control, 2003; 31:424–430.

21.

Archibald

, Phillips

, Monnet

et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis, 1997; 24:211–215.

22.

Monnet

, Archibald

, Phillips

et al. Antimicrobial use and resistance in eight U.S. hospitals: Complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol, 1998; 19:388–394.

23.

National Nosocomial Infections Surveillance System. NNIS Report: Data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control, 2003; 31:481–498.

24.

Lipsitch

, Levin

. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother, 1997; 41:363–373.

25.

Bonten

, Weinstein

. The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol, 1996; 17:193–200.

26.

Margreet

, Filius

, Gyssens

et al. Colonization and resistance dynamics of gram-negative bacteria in patients during and after hospitalization. Antimicrob Agents Chemother, 2005; 49:2879–2886.

Epidemiologic Trends,Occurrence of Extended-Spectrum β-Lactamase Production,and Performance of Ertapenem and Comparators in Patients with Intra-Abdominal Infections: Analysis of Global Trend Data from 2002–2007 from the SMART Study

Abstract

Abstract

Background:

Methods:

Results:

Conclusions:

Get full access to this article

References